Enable Therapeutics LLC

Framingham, MA · Biotech · Private

Fab fusion protein (VAL-0914) that delivers Neprilysin enzyme into cardiac muscle cells to degrade cytotoxic pre-amyloid oligomers

Grants
$701K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies$450,022
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Antibody-Enzyme Fusion for the Treatment of Myotubular Myopathy$251,034
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2793Forge Biologics Holdings, LLC—$160M
2794Empress Therapeutics——
2795Octant Bio——
2796Enable Therapeutics LLC——
2797RGENE, INC.——
2798Immunocore Holdings plc—$140M
2799Black Diamond Therapeutics—$140M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.